Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 8/20 | 0.44 |
| ▸ | CTSL | P07711 | 11/20 | 0.43 |
| ▸ | CTSV | O60911 | 10/20 | 0.43 |
| ▸ | CTSS | P25774 | 10/20 | 0.43 |
| ▸ | CTSK | P43235 | 7/20 | 0.43 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.41 |
| ▸ | KLK1 | P06870 | 2/20 | 0.41 |
| ▸ | MASP2 | O00187 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1432183 | 1.00 | CTSB (0.44) | CTSBCTSLCTSVCTSSCTSK | |
| SCHEMBL3153950 | 0.90 | CTSB (0.44) | CTSBCTSLCTSVCTSSCTSK | |
| SCHEMBL3153914 | 0.90 | CTSB (0.44) | CTSBCTSLCTSVCTSSCTSK | |
| SCHEMBL1431746 | 0.90 | CTSB (0.43) | CTSBCTSLCTSSCTSKKLKB1 | |
| SCHEMBL3147030 | 0.90 | CTSB (0.43) | CTSBCTSLCTSSCTSKKLKB1 | |
| SCHEMBL1432456 | 0.89 | CTSB (0.44) | CTSBCTSLCTSVCTSSCTSK | |
| SCHEMBL3144614 | 0.89 | CTSB (0.44) | CTSBCTSLCTSVCTSSCTSK | |
| SCHEMBL3148655 | 0.89 | KLKB1 (0.41) | HTRA1KLKB1KLK1MASP2 | |
| SCHEMBL3148667 | 0.89 | KLKB1 (0.41) | HTRA1KLKB1KLK1MASP2 | |
| SCHEMBL3149326 | 0.89 | KLKB1 (0.41) | HTRA1KLKB1KLK1MASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | claimed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | CTSB 2784/4885CTSL 2316/4885CTSV 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.